Clinical Report: 16-Week Data From SALWEEN Fill the Gap for Patients With PCV
Overview
The SALWEEN study demonstrates the efficacy and safety of faricimab in treating polypoidal choroidal vasculopathy (PCV), with significant visual acuity gains and anatomical improvements observed by week 16. The study reports a polyp closure rate of 51%, indicating promising outcomes for patients with this condition.
Background
Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration (AMD) that can lead to significant vision loss. Traditional clinical trials have often excluded patients with PCV, limiting the understanding of treatment efficacy in this population. The SALWEEN study aims to address this gap by evaluating faricimab's effectiveness in a dedicated cohort of PCV patients.
Data Highlights
By week 16, average best-corrected visual acuity (BCVA) gain was slightly more than seven letters, and central subfield thickness (CST) was just over 400 μm. The polyp closure rate at week 16 was 51%, with over 80% of eyes showing no active polyps.
Key Findings
- Average BCVA gain of slightly more than seven letters by week 16.
- CST reduction observed after the first four injections.
- Polyp closure rate of 51% at week 16, one of the highest reported for monotherapy.
- Over 80% of eyes had no active polyps based on indocyanine green angiography (ICG).
- Patients started with a baseline BCVA of 64 letters, indicating a relatively high initial visual function.
Clinical Implications
The findings from the SALWEEN study suggest that faricimab may be an effective treatment option for patients with PCV, providing both visual and anatomical improvements. Clinicians should consider incorporating faricimab into treatment plans for PCV, especially given the promising polyp closure rates.
Conclusion
The SALWEEN study offers encouraging early data on the use of faricimab in PCV, highlighting its potential to improve patient outcomes. Continued monitoring of long-term efficacy and safety will be essential as the study progresses.
References
- Ophthalmology Management, 2025 -- SALWEEN Results Presented at Euretina Show Durable PCV Treatment
- Infection — Immune Responses Following Sequential Administration of PCV13 and PPSV23 in Recipients of Kidney Transplants
- Open Forum Infectious Diseases — A Retrospective Study of Pneumocystis jirovecii Pneumonia in a Diverse Patient Population
- Bone Marrow Transplantation — Phase I Investigation of Placental Expanded Mesenchymal-Like Cells (PLX-R18) for Addressing Poor Graft Function Following Hematopoietic Cell Transplantation
- Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management
- Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial | Trials | JAMA Ophthalmology | JAMA Network
- Treatment of Polypoidal Choroidal Vasculopathy: Systematic Review and Meta-Analysis | QJM: An International Journal of Medicine | Oxford Academic
- A study evaluating the effectiveness and safety of faricimab (RO6867461) in participants with polypoidal choroidal vasculopathy
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.